Marked strain differences in the pharmacokinetics of an α4β1 integrin antagonist, 4-[1-[3-chloro-4-[N- (2-methylphenyl)-ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl] -methoxybenzoic acid (D01-4582), in Sprague-Dawley rats are associated with albumin genetic polymorphism

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 1, 2007, Pages 124-132

  Ito, Takashi ^a   Takahashi, Masayuki ^a   Sudo, Kenichi ^a   Sugiyama, Yuichi ^b  

^a DAIICHI SANKYO CO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [1 [3 CHLORO 4 [N (2 METHYLPHENYL) UREIDO]PHENYLACETYL] (4S) FLUORO (2S) PYRROLIDINE 2 YL]METHOXYBENZOIC ACID; ALBUMIN; BENZOIC ACID DERIVATIVE; D 01 4582; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CELL ISOLATION; CONTROLLED STUDY; DNA SEQUENCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PROTEIN BINDING; DRUG UPTAKE; GENETIC POLYMORPHISM; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; RAT STRAIN;

ALBUMINS; ANIMALS; BILE; DNA, COMPLEMENTARY; HEPATOCYTES; INTEGRIN ALPHA4BETA1; MALE; PHENYLUREA COMPOUNDS; POLYMORPHISM, GENETIC; PROTEIN BINDING; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 33845899457     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.111948     Document Type: Article

References (33)

1. Benet LZ and Hoener BA (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115-121.
2. Curry S, Mandelkow H, Brick P, and Franks N (1998) Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 5:827-835.
3. Evans WE and McLeod HL (2003) Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348:538-549.
4. Fehske KJ, Schlafer U, Wollert U, and Muller WE (1982) Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone. Mol Pharmacol 21:387-393.
5. Ferrand N and Rocha J (1992) Demonstration of serum albumin (ALB) polymorphism in wild rabbits, Oryctolagus cuniculus, by means of isoelectric focusing. Anim Genet 23:275-278.
6. Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, and Curry S (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 353:38-52.
7. Guex N and Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18:2714-2723.
8. Imamura Y and Shimada H (2005) Differential pharmacokinetics of acetohexamide in male Wistar-Imamichi and Sprague-Dawley rats: role of microsomal carbonyl reductase. Biol Pharm Bull 28:185-187.
9. Kim DC, Sugiyama Y, Saitoh H, Fuwa T, Iga T, and Hanano M (1988) Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues. J Pharm Sci 77:200-207.
10. Kosa T, Maruyama T, and Otagiri M (1997) Species differences of serum albumins: I. Drug binding sites. Pharm Res (NY) 14:1607-1612.
11. Kragh-Hansen U, Brennan SO, Galliano M, and Sugita O (1990a) Binding of warfarin, salicylate, and diazepam to genetic variants of human serum albumin with known mutations. Mol Pharmacol 37:238-242.
12. Kragh-Hansen U, Minchiotti L, Brennan SO, and Sugita O (1990b) Hormone binding to natural mutants of human serum albumin. Eur J Biochem 193:169-174.
13. Kragh-Hansen U, Pedersen AO, Galliano M, Minchiotti L, Brennan SO, Tarnoky AL, Franco MH, and Salzano FM (1996) High-affinity binding of laurate to naturally occurring mutants of human serum albumin and proalbumin. Biochem J 320:911-916.
14. Liu K, Kato Y, Narukawa M, Kim D, Hanano M, Higuchi O, Nakamura T, and Sugiyama Y (1992) Importance of the liver in plasma clearance of hepatocyte growth factor in rats. Am J Physiol 263:G642-G649.
15. Matsushita Y, Gouda H, Tsujishita H, and Hirono S (1998) Determination of binding conformations of drugs to human serum albumin by transferred nuclear Overhauser effect measurements and conformational analyses using high-temperature molecular dynamics calculations. J Pharm Sci 87:379-386.
16. Meijer D, Smit J, Hooiveld G, Montfoort J, Jansen P, and Muller M (1999) The molecular basis for hepatobiliary transport of organic cations and organic anions, in Membrane Transporters as Drug Targets (Amidon GL and Sadee W eds) pp 89-157, Kluwer Academic/Plenum Publishers, New York.
17. Panepucci L and Vicente V (1991) Comparative gene frequencies between the Canchim breed of Brazil beef cattle and their foundation breeds. Comp Biochem Physiol B 98:165-167.
18. Peitsch MC (1995) Protein modeling. Biotechnology 13:658-660.
19. Peters JT (1996) All About Albumin, Academic, San Diego, CA.
20. Petersen CE, Ha CE, Harohalli K, Park DS, and Bhagavan NV (2000) Familial dysalbuminemic hyperthyroxinemia may result in altered warfarin pharmacokinetics. Chem Biol Interact 124:161-172.
21. Petersen CE, Scottolini AG, Cody LR, Mandel M, Reimer N, and Bhagavan NV (1994) A point mutation in the human serum albumin gene results in familial dysalbuminaemic hyperthyroxinaemia. J Med Genet 31:355-359.
22. Pirmohamed M and Park BK (2001) Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 22:298-305.
23. Sadee W (1998) Genomics and drugs: finding the optimal drug for the right patient. Pharm Res (NY) 15:959-963.
24. Saito K, Sakai N, Kim HS, Ishizuka M, Kazusaka A, and Fujita S (2004) Strain differences in diazepam metabolism at its three metabolic sites in Sprague-Dawley, Brown Norway, Dark Agouti, and Wistar strain rats. Drug Metab Dispos 32:959-965.
25. Sakai N, Saito K, Kim HS, Kazusaka A, Ishizuka M, Funae Y, and Fujita S (2005) Importance of CYP2D3 in polymorphism of diazepam p-hydroxylation in rats. Drug Metab Dispos 33:1657-1660.
26. Schwede T, Kopp J, Guex N, and Peitsch MC (2003) SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 31:3381-3385.
27. Sudlow G, Birkett DJ, and Wade DN (1975) The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 11:824-832.
28. Tribut O, Lessard Y, Reymann JM, Allain H, and Bentue-Ferrer D (2002) Pharmacogenomics. Med Sci Monit 8:RA152-RA163.
29. Yamasaki K, Maruyama T, Kragh-Hansen U, and Otagiri M (1996) Characterization of site I on human serum albumin: concept about the structure of a drug binding site. Biochim Biophys Acta 1295:147-157.
30. Yamazaki M, Suzuki H, Hanano M, Tokui T, Komai T, and Sugiyama Y (1993) Na+-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36-G44.
31. Wada N, Chiba H, Shimizu C, Kijima H, Kubo M, and Koike T (1997) A novel missense mutation in codon 218 of the albumin gene in a distinct phenotype of familial dysalbuminemic hyperthyroxinemia in a Japanese kindred. J Clin Endocr Metab 82:3246-3250.
32. Watanabe H, Yamasaki K, Kragh-Hansen U, Tanase S, Harada K, Suenaga A, and Otagiri M (2001) In vitro and in vivo properties of recombinant human serum albumin from Pichia pastoris purified by a method of short processing time. Pharm Res (NY) 18:1775-1781.
33. Watkins S, Sakamoto Y, Madison J, Davis E, Smith DG, Dwulet J, and Putnam FW (1993) cDNA and protein sequence of polymorphic macaque albumins that differ in bilirubin binding. Proc Natl Acad Sci USA 90:2409-2413.